BioCryst gets four HAE abstracts accepted for 2026 allergy meeting
AI Summary- BioCryst Pharmaceuticals had four hereditary angioedema abstracts accepted for the 2026 allergy meeting.
- 2029 consensus forecasts cited $930.1 million revenue and $131.3 million earnings.
- The FDA approved a 150 mg ORLADEYO pellet formulation for adults and adolescents.